UCB recently announced the positive results of the Phase 3 BE READY study, which evaluated the safety and efficacy of bimekizumab in patients with moderate-to-severe chronic plaque psoriasis. These results come from the second of three Phase 3 studies to evaluate the IL-17A and IL-17F inhibitor bimekizumab vs placebo.
These data follow the positive clinical results recently reported from the Phase 3 BE VIVID study, which evaluated the safety and efficacy of bimekizumab vs placebo and ustekinumab, in adults with moderate-to-severe plaque psoriasis. The BE VIVID study met all primary and ranked secondary endpoints showed statistically significant superiority for bimekizumab treatment compared to placebo and ustekinumab in achieving skin clearance and disease improvement at week 16.